流感季来临+跟踪指数股息率3.18%，中药ETF(159647)配置价值凸显

Core Viewpoint - The Chinese traditional medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by rising flu cases and the performance of key stocks in the industry [1][2]. Group 1: Market Performance - As of November 24, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.68%, with a one-year dividend yield of 3.18% [1]. - Key component stocks such as Jiaying Pharmaceutical (002198) increased by 4.48%, Zhongsheng Pharmaceutical (002317) by 2.86%, and others also showed positive growth [1]. - The Zhongzheng Traditional Chinese Medicine ETF (159647) increased by 0.40%, with the latest price at 1 yuan [1]. Group 2: Flu Trends and Impact - The National Influenza Center reported that the ILI% in southern hospitals was 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [1]. - Northern hospitals reported an ILI% of 6.1%, also higher than the previous week and exceeding levels from the last three years [1][2]. - The rising flu positivity rates in both southern and northern regions are attributed to lower immunity against the H3N2 strain and an earlier onset of the flu season this year [2]. Group 3: Industry Outlook - The flu season for 2025-2026 is expected to peak higher than the previous year, leading to increased demand for respiratory infection-related products [2]. - The traditional Chinese medicine sector is anticipated to face short-term performance pressure but is expected to benefit from policies related to centralized procurement and basic medicine, as well as innovation-driven growth [2]. - The top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index account for 54.92% of the index, indicating a concentrated market structure [3].